Table 5.
Results of the neuropsychological tests and the questionnaires of memory and mood
| Group | 0 month (baseline§) | 1 month (treatment) | 3 months (treatment) | 6 months (treatment) | 9 months (follow-up) | |
|---|---|---|---|---|---|---|
| RBMT | Placebo | 18.3 ± 0.52 | 18.3 ± 0.91 | 20.4 ± 0.57** | 22.2 ± 0.46*** | 22.2 ± 0.48*** |
| PS100 | 18.4 ± 0.59 | 19.4 ± 0.44 | 20.1 ± 0.44 | 22.3 ± 0.29*** | 22.6 ± 0.24*** | |
| PS300 | 18.0 ± 0.49 | 19.5 ± 0.44 | 19.1 ± 0.50 | 21.6 ± 0.32*** | 21.6 ± 0.41*** | |
| HDS-R | Placebo | 28.0 ± 0.38 | — | — | 29.1 ± 0.25* | 28.5 ± 0.29 |
| PS100 | 27.8 ± 0.42 | — | — | 29.2 ± 0.22* | 29.2 ± 0.19* | |
| PS300 | 27.4 ± 0.32 | — | — | 28.4 ± 0.31* | 28.6 ± 0.35** | |
| MMSE | Placebo | 27.9 ± 0.38 | — | — | 28.5 ± 0.37 | 28.2 ± 0.35 |
| PS100 | 27.7 ± 0.39 | — | — | 29.0 ± 0.26* | 29.2 ± 0.29** # | |
| PS300 | 27.6 ± 0.39 | — | — | 28.0 ± 0.30 | 28.2 ± 0.35 | |
| EMC | Placebo | 29.1 ± 1.20 | 26.8 ± 1.13 | 26.1 ± 1.12 | 24.6 ± 0.90** | 25.1 ± 1.09* |
| PS100 | 28.8 ± 1.24 | 28.0 ± 1.26 | 27.8 ± 1.49 | 27.4 ± 1.25 | 27.2 ± 1.46 | |
| PS300 | 28.7 ± 1.04 | 27.0 ± 0.97 | 26.3 ± 1.04 | 26.0 ± 1.02 | 24.6 ± 0.98* | |
| GDS | Placebo | 10.7 ± 1.05 | — | — | 7.1 ± 0.91* | 5.2 ± 0.81*** |
| PS100 | 10.7 ± 1.10 | — | — | 8.7 ± 1.21 | 7.1 ± 1.02* | |
| PS300 | 11.4 ± 1.51 | — | — | 8.9 ± 1.38 | 8.1 ± 1.35 | |
Values are mean ± SEM. §The values at screening were used as baseline values. Subjects started taking the samples within one month after screening. The follow-up period consisted of 3 months after finishing the 6 months of sample intake, during which subjects took no sample. *p<0.05, **p<0.01, ***p<0.001 vs baseline, #p<0.05 vs placebo group (Steel’s multi-comparison test).